Reprogramming and iPSC culture considerations for translational research
Available to view on demand
An overview of practical considerations for generating iPSCs that can be effectively transitioned toward clinical trials.
In order for iPSCs to realize their full clinical potential, reprogramming strategies and subsequent iPSC culture conditions must comply with clinical guidelines. This webinar will discuss some of the key crossroads and challenges that researchers face when choosing a method for iPSC generation, as well as provide perspective to find a balance between safety, efficacy, definition, and clinical compatibility in both reprogramming technologies and iPSC culture systems.
This webinar was recorded on 22 March 2017.
What will you learn?
- Challenges in reprogramming balancing safety and efficacy
- Optimizing the iPSC culture system for clinical applications
Who may this interest?
- Researchers working with pluripotent stem cells
- Researchers new to reprogramming and iPSC culture
- Labs working in the field of regenerative medicine
- Stem cell core facilities
- Cell therapy companies
Speaker
Lia Kent
Scientific Training and Support Manager
Biological Industries USA
Lia Kent began her career with human pluripotent stem cells in 2003 at WiCell Research Institute and in the lab of Dr. James Thomson at the University of Wisconsin-Madison. For the past 14 years, she has been providing technical support and hands-on training for scientists across the world on a variety of methods, including human pluripotent stem cell culture techniques, cutting-edge reprogramming technologies, and best practices in cell culture laboratory maintenance and sterility. She currently manages technical training and scientific support at Biological Industries USA.
For a full list of other webinars available on RegMedNet please see here.